valsartan has been researched along with Disease Exacerbation in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.64) | 18.2507 |
| 2000's | 19 (31.15) | 29.6817 |
| 2010's | 33 (54.10) | 24.3611 |
| 2020's | 8 (13.11) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R; Bhatt, AS; Claggett, BL; Fonarow, GC; Greene, SJ; McMurray, JJV; Solomon, SD; Vaduganathan, M | 1 |
| Alba, PR; Bress, AP; Choi, ME; Dodson, JA; He, T; King, JB; LaFleur, J; Levitan, EB; Mohanty, AF; Patterson, OV; Russo, PA; Vardeny, O | 1 |
| Butler, J; Camacho, A; Felker, GM; Januzzi, JL; Maisel, AS; Piña, IL; Prescott, MF; Rocha, R; Solomon, SD; Williamson, KM | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Agostoni, P; Bonomi, A; de Martino, F; Gugliandolo, P; Magini, A; Mapelli, M; Mattavelli, I; Paolillo, S; Rovai, S; Salvioni, E; Sassi, V; Vignati, C | 1 |
| Danzi, GB; De Maria, R; Di Tano, G; Loffi, M; Verde, S | 1 |
| Dong, Z; Li, G; Li, L; Liang, Y; Liu, E; Liu, T; Niu, X; Wang, J; Yang, Y; Zhao, Z | 1 |
| Haynes, R; Judge, PK | 1 |
| Hu, J; Liu, S; Liu, W; Lu, S; Wang, Y; Wang, Z; Zeng, X | 1 |
| Guo, J; Wong, PC; Zhang, A | 1 |
| Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S | 1 |
| Dalman, RL; Iida, Y; Miyata, M; Xu, B; Xuan, H | 1 |
| Chen, C; Gan, L; Li, X; Luo, H; Zhou, Q; Zhu, M | 1 |
| Coppey, LJ; Davidson, EP; Obrosov, A; Shevalye, H; Yorek, MA | 1 |
| Bafor, EE; Bolanle, IO; Omogbai, EKI | 1 |
| Bouabdallaoui, N; Claggett, B; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Dong, Z; Li, G; Li, L; Liang, Y; Liu, E; Liu, T; Niu, X; Qi, W; Zhao, Z | 1 |
| Goldstein, BA; Holman, RR; Pagidipati, NJ; Pencina, MJ; Phelan, M; Stuart, EA | 1 |
| Amano, T; Harada, K; Ichimiya, S; Ishii, H; Kanashiro, M; Kobayashi, M; Kurebayashi, N; Marui, N; Murohara, T; Sone, T; Suzuki, S; Tsuboi, H; Uetani, T; Yoshikawa, D | 1 |
| Ge, Y; Hou, J; Jin, B; Li, S; Liu, Z; Shi, M; Xie, H; Zhang, H | 1 |
| Cheung, AK; Huang, Y; Liu, X; Zhou, G | 1 |
| Guo, T; Hao, P; Kong, J; Li, D; Meng, X; Yang, J; Zhang, C; Zhang, K; Zhang, M; Zhang, Y | 1 |
| Baigent, C; Haynes, R; Judge, P; Landray, MJ | 1 |
| Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z | 1 |
| Andersen, K; Arango, JL; Arnold, JM; Bělohlávek, J; Böhm, M; Boytsov, S; Burgess, LJ; Cabrera, W; Calvo, C; Chen, CH; Desai, AS; Duarte, YC; Dukat, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzàlez-Medina, A; Hagège, AA; Huang, J; Katova, T; Kiatchoosakun, S; Kim, KS; Kozan, Ö; Lefkowitz, MP; Llamas, EB; Martinez, F; McMurray, JJ; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, FJ; Refsgaard, J; Rizkala, AR; Rosenthal, A; Rouleau, JL; Senni, M; Shi, VC; Sibulo, AS; Silva-Cardoso, J; Solomon, SD; Squire, IB; Starling, RC; Swedberg, K; Teerlink, JR; Vanhaecke, J; Vinereanu, D; Wong, RC; Zile, M | 1 |
| Krum, H | 1 |
| Alkhoder, A; Binongo, JN; Dhawan, SS; Jones, DP; Oshinski, JN; Quyyumi, AA; Ramadan, R | 1 |
| Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJ; Okumura, N; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, S; Swedberg, K; Zile, M | 1 |
| Claggett, B; Desai, A; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Sabbah, HN | 1 |
| Bethel, M; Boolell, M; Califf, RM; Duggal, A; Haffner, SM; Holman, RR; McMurray, J | 1 |
| Aoki, M; Fujiwara, Y; Makino, H; Miyake, T; Morishita, R; Nishimura, M; Shiraya, S; Yamakawa, S | 1 |
| Geshi, E; Katagiri, T; Mochizuki, S; Nakano, H; Nanjyo, S; Sato, N; Shibata, T; Suzuki, H; Takano, T; Tanaka, K; Yagi, H; Yamazaki, J | 1 |
| Miura, T; Yuda, S | 1 |
| Braga, MF; Leiter, LA | 1 |
| Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A | 1 |
| Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Lim, DS; Park, JH | 1 |
| Li, B; Oite, T; Qi, SH; Song, SM; Wang, CC; Xing, L; Yang, BF | 1 |
| Amigoni, M; Califf, R; Køber, L; Levine, RA; McMurray, JJ; Meris, A; Pfeffer, MA; Solomon, SD; Thune, JJ; Velazquez, E; Verma, A | 1 |
| Altieri, PI; Cangiano, JL; Crespo, MJ; Escobales, N | 1 |
| Aono, J; Higaki, J; Horiuchi, M; Inoue, K; Iwai, M; Nagai, T; Nishimura, K; Ogimoto, A; Okayama, H; Suzuki, J | 1 |
| Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M | 1 |
| Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T | 1 |
| Endoh, M; Ideura, T; Kamata, K; Kimura, K; Suzuki, D; Tamura, K; Toya, Y; Umemura, S; Yasuda, T; Yoshimura, A | 1 |
| Benigni, A; Donadoni, C; Fassi, A; Gagliardini, E; Lepre, MS; Remuzzi, A; Remuzzi, G; Sangalli, F | 1 |
| Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H | 1 |
| Bertocchi, F; Ceconi, C; De Tommasi, E; Ferrari, R; Francolini, G; Guida, P; Iacoviello, M; Massari, F; Pitzalis, MV; Rizzon, P; Romito, R | 1 |
| Crijns, HJ; Folkeringa, RJ; Pinto, YM | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tan, LB; Tognoni, G; Vago, T; Wong, M | 1 |
| Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F | 1 |
| Chen, N; Hao, L; Sun, G; Wang, W; Wu, K; Zhang, Y; Zhou, T | 1 |
| Khan, F; Kumagai, N; Mahmood, J; Morioka, T; Oite, T; Okada, S | 1 |
| Coll, JR; Estacio, RO; Schrier, RW; Tran, ZV | 1 |
| Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Cohn, JN; Duprez, DA; Florea, ND; Jones, K | 1 |
| Victor, RG | 1 |
| Goldstein, S; Levine, TB; Mishima, T; Sabbah, HN; Sharov, VG; Shimoyama, H; Tanimura, M | 1 |
| Cooper, ME; Gibbs, NJ; Kelly, DJ; Skinner, SL; Wilkinson-Berka, JL | 1 |
| Allen, TJ; Bertram, JF; Cooper, ME; Gilbert, RE; Hulthen, UL; Kelly, DJ; Mifsud, SA; Wilkinson-Berka, JL | 1 |
8 review(s) available for valsartan and Disease Exacerbation
| Article | Year |
|---|---|
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
[Neprilysin inhibition and chronic kidney disease].
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Diuresis; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Models, Biological; Molecular Targeted Therapy; Natriuresis; Natriuretic Peptides; Neprilysin; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Humans; Receptor, Angiotensin, Type 1; Telmisartan; Valsartan | 2018 |
Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Natriuresis; Nephrology; Neprilysin; Proteinuria; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valsartan | 2015 |
Sacubitril/valsartan (Entresto) for heart failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiotonic Agents; Disease Progression; Drug Combinations; Drug Interactions; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2015 |
Silent disease progression in clinically stable heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Apoptosis; Atrial Natriuretic Factor; Biphenyl Compounds; Calcium; Disease Progression; Diuretics; Drug Combinations; Fibrosis; Heart Failure; Humans; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stress, Mechanical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2017 |
Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function | 2009 |
Pathophysiology of target-organ disease: does angiotensin II remain the key?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
20 trial(s) available for valsartan and Disease Exacerbation
| Article | Year |
|---|---|
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Disease Progression; Drug Combinations; Drug Labeling; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Time Factors; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left | 2021 |
Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Blood Pressure; Disease Progression; Drug Therapy, Combination; Female; Fluvastatin; Heart Rate; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Valsartan | 2020 |
Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.
Topics: Adult; Biopsy; Cell Line; Cell Proliferation; Chemokine CCL20; Chemokine CCL22; Chemokine CCL27; Chemotaxis; Coculture Techniques; Disease Progression; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Glucosides; Humans; Immunosuppressive Agents; Male; Mesangial Cells; Middle Aged; Phenols; Proteinuria; Rehmannia; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta1; Treatment Outcome; Valsartan; Young Adult | 2018 |
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Disease Progression; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2018 |
Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non-permanent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Disease Progression; Female; Fluvastatin; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Valsartan | 2018 |
Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Combined Modality Therapy; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypertension; Image Interpretation, Computer-Assisted; Imidazoles; Long-Term Care; Male; Middle Aged; Tetrazoles; Ultrasonography, Interventional; Valine; Valsartan | 2013 |
Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial.
Topics: Adult; Aged; Diabetic Nephropathies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Prospective Studies; Tetrazoles; Treatment Outcome; Tripterygium; Valine; Valsartan | 2013 |
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Isoxazoles; Kidney; Leflunomide; Male; Platelet Aggregation Inhibitors; Proteinuria; Tetrazoles; Ticlopidine; Time Factors; Treatment Outcome; Valine; Valsartan | 2015 |
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Valsartan | 2015 |
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Topics: Aged; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Endpoint Determination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chi-Square Distribution; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Kidney; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Dropouts; Proportional Hazards Models; Prospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Case-Control Studies; Disease Progression; Double-Blind Method; Drug Combinations; Drug Substitution; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cyclohexanes; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Research Design; Tetrazoles; Valine; Valsartan | 2008 |
Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Topics: Adiponectin; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Coronary Stenosis; Diabetes Mellitus, Type 2; Disease Progression; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Hypertension; Interleukin-6; Male; Middle Aged; Neointima; Prospective Studies; Single-Blind Method; Sirolimus; Telmisartan; Tetrazoles; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography, Interventional; Valine; Valsartan | 2011 |
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction.
Topics: Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Disease Progression; Echocardiography, Doppler, Color; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Monitoring, Physiologic; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prospective Studies; Reference Values; Reproducibility of Results; Risk Assessment; ROC Curve; Severity of Illness Index; Sex Factors; Statistics, Nonparametric; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood Pressure; Comorbidity; Creatinine; Disease Progression; Female; Humans; Hypertension; Japan; Male; Middle Aged; Proteinuria; Renal Insufficiency, Chronic; Renal Replacement Therapy; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Lisinopril; Male; Middle Aged; Norepinephrine; Tetrazoles; Valine; Valsartan | 2003 |
Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Colorado; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2006 |
Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Disease Progression; Double-Blind Method; Exercise Test; Female; Fluorescein Angiography; Health Status Indicators; Heart Diseases; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Predictive Value of Tests; Tetrazoles; Valine; Valsartan | 2007 |
33 other study(ies) available for valsartan and Disease Exacerbation
| Article | Year |
|---|---|
Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Drug Combinations; Drug Substitution; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Valsartan; Ventricular Function, Left; Veterans Health Services | 2019 |
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Disease Progression; Drug Combinations; Heart Failure; Hospitalization; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Disease Progression; Drug Combinations; Female; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions].
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Biphenyl Compounds; Chronic Disease; Continuity of Patient Care; Coronavirus Infections; COVID-19; Delivery of Health Care; Disease Progression; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Pandemics; Pneumonia, Viral; Quarantine; Recurrence; SARS-CoV-2; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Telephone; Tetrazoles; Valsartan; Withholding Treatment | 2020 |
Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Body Weight; Disease Models, Animal; Disease Progression; Drug Combinations; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan | 2021 |
The renal and cardiovascular effects of natriuretic peptides.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Tetrazoles; Valsartan | 2017 |
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Diet, High-Fat; Disease Progression; Drug Combinations; Male; Neprilysin; Neural Conduction; Neuroprotective Agents; Protease Inhibitors; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Resistance | 2018 |
Effects of amlodipine and valsartan on glibenclamide-treated streptozotocin-induced diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Drug Interactions; Glyburide; Hypoglycemic Agents; Male; Rats, Wistar; Risk Assessment; Streptozocin; Time Factors; Valsartan | 2018 |
An outcome model approach to transporting a randomized controlled trial results to a target population.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progression; Electronic Health Records; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Machine Learning; Nateglinide; Outcome Assessment, Health Care; Prediabetic State; Randomized Controlled Trials as Topic; Translational Research, Biomedical; Valsartan | 2019 |
Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Extracellular Matrix Proteins; Fibronectins; Gene Expression Regulation; Inflammation; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Cortex; Kidney Glomerulus; Membrane Proteins; Mice; Oxidative Stress; Plasminogen Activator Inhibitor 1; Podocytes; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta1; Treatment Outcome; Valine; Valsartan; WT1 Proteins | 2014 |
Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Proliferation; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Male; Mesangial Cells; Oxidative Stress; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Valsartan; Vascular Endothelial Growth Factor A | 2015 |
Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2015 |
Effect of Angiotensin II Type I Receptor Blockade with Valsartan on Carotid Artery Atherosclerosis: A Double Blind Randomized Clinical Trial Comparing Valsartan and Placebo (EFFERVESCENT).
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Carotid Artery Diseases; Carotid Intima-Media Thickness; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Treatment Outcome; Valsartan; Young Adult | 2016 |
Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Blood Pressure; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neutrophil Infiltration; NF-kappa B; Pancreatic Elastase; Rats; Rats, Wistar; Tetrazoles; Ultrasonography; Valine; Valsartan | 2008 |
Are treatment effects of ACEI and ARB in post-MI patients homogeneous?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Asian People; Disease Progression; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording | 2010 |
Angiotensin receptor blockade attenuates glomerulosclerosis progression by promoting VEGF expression and bone marrow-derived cells recruitment.
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Western; Bone Marrow; Bone Marrow Transplantation; Disease Progression; Female; Fluorescent Antibody Technique; Glomerulosclerosis, Focal Segmental; Green Fluorescent Proteins; Immunoenzyme Techniques; Isoantibodies; Kidney Glomerulus; Male; Nephrectomy; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Angiotensin; Tetrazoles; Thy-1 Antigens; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2012 |
Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathy, Dilated; Cricetinae; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fumarates; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2012 |
Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Carotid Artery Diseases; Carotid Artery, Common; CD36 Antigens; Disease Models, Animal; Disease Progression; Focal Adhesion Kinase 1; Gene Deletion; JNK Mitogen-Activated Protein Kinases; Lipids; Lipoproteins, LDL; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Rupture, Spontaneous; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |
Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Gene Expression Regulation; Hepatocytes; In Situ Nick-End Labeling; Liver Cirrhosis, Experimental; Mitochondria, Liver; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Body Weight; Collagen Type III; Disease Progression; Kidney Diseases; Kidney Glomerulus; Lisinopril; Macrophages; Male; Monocytes; Proteinuria; Rats; Rats, Wistar; Renal Circulation; Tetrazoles; Valine; Valsartan | 2002 |
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Progression; Echocardiography; Enzyme Activation; Heart Failure; Hypertension; Male; Myocardium; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-epsilon; Protein Transport; Rats; Rats, Inbred Dahl; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
Aldosterone levels after angiotensin receptor blocker treatment.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2004 |
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Disease Progression; Echocardiography; Heart Failure; Heart Ventricles; Humans; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke Volume; Survival Rate; Tetrazoles; Valine; Valsartan | 2006 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex | 2006 |
Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Dendritic Cells; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Kidney Tubules; Membrane Glycoproteins; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2006 |
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Drug Implants; Female; Gene Expression Regulation; Glomerulonephritis; Isoantibodies; Kidney Glomerulus; Microcirculation; Nephrectomy; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2006 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan | 2007 |
Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiac Output, Low; Disease Progression; Dogs; Dose-Response Relationship, Drug; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 1999 |
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Female; Heterozygote; Kidney; Perindopril; Rats; Renin; Tetrazoles; Valine; Valsartan | 2001 |
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Basement Membrane; Blood Pressure; Diabetes Mellitus, Experimental; Disease Models, Animal; Disease Progression; Humans; Kidney; Kidney Glomerulus; Male; Organ Size; Ramipril; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |